RecruitingInterventionalPhase 1Phase 2Last updated Aug 11, 2026

A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension

A Phase 1/2 Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety, Tolerability, and Efficacy of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX340) for In Vivo Editing of the Angiotensinogen (AGT) Gene in Participants With Hypertension

Overview

ClinicalTrials.gov ID: NCT07758634
Lead Sponsor: CRISPR Therapeutics AGINDUSTRY
Brief Summary: A Study of CTX340 in Participants with Uncontrolled Hypertension.
Study Type: Interventional
Phase

Status

Overall Status: Recruiting
Start Date: Aug 8, 2026Estimated
Primary Completion Date: Jul 1, 2028Estimated
Completion Date: Jul 1, 2029Estimated

Study Record Dates

First Submitted: Aug 6, 2026
First Submitted that Met QC Criteria: Aug 6, 2026
First Posted: Aug 11, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 6, 2026
Last Update Posted: Aug 11, 2026Actual
Last Verified: Aug 2026

NCT07491172Recruiting

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

NCT03934307Completed

A Study to Evaluate ALN-AGT01 in Patients With Hypertension

NCT03019653Completed

Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome

NCT03714776Completed

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure

NCT06780033Terminated

A Study to Evaluate ART101 in Adult Participants With Hypertension

NCT07473752Completed

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects